- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:30 | US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week's pricings | 1 | Renaissance Capital | ||
| Fr | CITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| CITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | City Therapeutics' Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver | 1 | MedCity News | ||
| Fr | City Therapeutics glänzt beim Börsendebüt nach aufgestocktem $200-Millionen-Börsengang | 1 | Investing.com Deutsch | ||
| Fr | Börsengang von City Therapeutics: Hälfte der Zeichnungsaufträge geht laut Bericht leer aus | 2 | Investing.com Deutsch | ||
| Fr | City Therapeutics prices upsized IPO at $18, the midpoint of the range | 1 | Renaissance Capital | ||
| Fr | City Therapeutics prices upsized IPO at $18 per share | 2 | Investing.com | ||
| Fr | City Therapeutics Announces Pricing of Upsized Initial Public Offering | 2 | GlobeNewswire (USA) | ||
| Di | CITY THERAPEUTICS, INC. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 09.10. | RNA interference biotech City Therapeutics sets terms for $175 million IPO | 1 | Renaissance Capital | ||
| 09.10. | CITY THERAPEUTICS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 25.09. | ADARx scores upsized $446M IPO, while fellow RNA biotech City Therapeutics maps out Nasdaq plans | 3 | FierceBiotech | ||
| 25.09. | RNA interference biotech City Therapeutics files for a $100 million IPO | 1 | Renaissance Capital | ||
| 24.09. | Drug developer City Therapeutics files for US IPO | 1 | Reuters | ||
| 24.09. | CITY THERAPEUTICS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 09.06. | City Therapeutics Raises $99.5 Million Series B to Advance Next-Generation RNAi Therapies | 1 | pulse2.com | ||
| 09.06. | City Therapeutics Raises $99.5M in Series B Funding | 1 | FinSMEs | ||
| 10.11.25 | City Therapeutics, Inc.: City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases | 368 | Business Wire | Company plans to initiate a Phase 1 study in early 2026 with initial human data expected late 2026 Company's first clinical-stage program headlines a diverse and novel pipeline poised to deliver... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| IMMUNOVANT | 26,730 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here's What You Should Know | ||
| PRAXIS PRECISION MEDICINES | 241,79 | +0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,320 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,950 | 0,00 % | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | ||
| ERASCA | 13,375 | -0,11 % | Erasca drops after sacking COO | ||
| MODERNA | 193,00 | -0,52 % | Nach 600 % mit Moderna! Cardiol Therapeutics vor Neubewertung! Analysten sehen massives Kurspotenzial! | Mit über 600 % Kursgewinn ist die Aktie von Moderna der Performance-Spitzenreiter im Nasdaq im laufenden Jahr. Damit dürfte viel Zukunftspotenzial eingepreist sein. Dies sieht auch die Citigroup so... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,550 | +0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| NURIX THERAPEUTICS | 24,400 | 0,00 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,050 | +0,05 % | Tango Therapeutics, Inc.: Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | ||
| TARSUS PHARMACEUTICALS | 68,06 | -0,01 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,840 | +0,07 % | Why Is Arcutis Biotherapeutics Stock Surging Thursday? | ||
| SUMMIT THERAPEUTICS | 14,650 | +0,14 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| CG ONCOLOGY | 59,92 | +0,12 % | CG Oncology appoints Isabel Kalofonos as chief commercial officer |
Das Unternehmen CITY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 22,030 Euro und damit -1,65 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITY THERAPEUTICS INC finden Sie auf Wallstreet Online.